Inactivated Vaccines Market Size to Hit USD 75.09 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Inactivated Vaccines Market

5.1. COVID-19 Landscape: Inactivated Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Inactivated Vaccines Market, By Vaccine Type

8.1. Inactivated Vaccines Market Revenue and Volume, by Vaccine Type

8.1.1. Whole Virus Inactivated Vaccines

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Split-Virion Inactivated Vaccines

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Subunit Inactivated Vaccines

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Combination Inactivated Vaccines

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Adjuvanted Inactivated Vaccines

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Inactivated Vaccines Market, By Disease Indication

9.1. Inactivated Vaccines Market Revenue and Volume, by Disease Indication

9.1.1. Polio

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Influenza

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. COVID-19

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Hepatitis A

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Rabies

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Japanese Encephalitis

9.1.6.1. Market Revenue and Volume Forecast

9.1.7. Cholera

9.1.7.1. Market Revenue and Volume Forecast

9.1.8. Pertussis

9.1.8.1. Market Revenue and Volume Forecast

9.1.9. Tick-Borne Encephalitis

9.1.9.1. Market Revenue and Volume Forecast

9.1.10. Combination Indications

9.1.5.10.1. Market Revenue and Volume Forecast

Chapter 10. Global Inactivated Vaccines Market, By Age Group

10.1. Inactivated Vaccines Market Revenue and Volume, by Age Group

10.1.1. Pediatrics (0–18 years)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Adults

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Geriatrics

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Snacks

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Travelers & At-Risk Populations

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Inactivated Vaccines Market, By End User

11.1. Inactivated Vaccines Market Revenue and Volume, by End User

11.1.1. Public Immunization Programs

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Private Clinics & Hospitals

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Military & Emergency Preparedness

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Travel & Occupational Health Centers

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Inactivated Vaccines Market, By Distribution Channel

12.1. Inactivated Vaccines Market Revenue and Volume, by Distribution Channel

12.1.1. Government Supply Contracts (e.g., UNICEF, Gavi, WHO)

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Hospital Pharmacies

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Retail Pharmacies

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Direct Institutional Sales

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Inactivated Vaccines Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Vaccine Type

13.1.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.3. Market Revenue and Volume Forecast, by Age Group

13.1.4. Market Revenue and Volume Forecast, by End User

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.1.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.6.3. Market Revenue and Volume Forecast, by Age Group

13.1.6.4. Market Revenue and Volume Forecast, by End User

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Vaccine Type

13.1.7.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.7.3. Market Revenue and Volume Forecast, by Age Group

13.1.7.4. Market Revenue and Volume Forecast, by End User

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.3. Market Revenue and Volume Forecast, by Age Group

13.2.4. Market Revenue and Volume Forecast, by End User

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.6.3. Market Revenue and Volume Forecast, by Age Group

13.2.7. Market Revenue and Volume Forecast, by End User

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.9.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.9.3. Market Revenue and Volume Forecast, by Age Group

13.2.10. Market Revenue and Volume Forecast, by End User

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.12.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.12.3. Market Revenue and Volume Forecast, by Age Group

13.2.12.4. Market Revenue and Volume Forecast, by End User

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.14.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.14.3. Market Revenue and Volume Forecast, by Age Group

13.2.14.4. Market Revenue and Volume Forecast, by End User

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.3. Market Revenue and Volume Forecast, by Age Group

13.3.4. Market Revenue and Volume Forecast, by End User

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.6.3. Market Revenue and Volume Forecast, by Age Group

13.3.6.4. Market Revenue and Volume Forecast, by End User

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.8.3. Market Revenue and Volume Forecast, by Age Group

13.3.8.4. Market Revenue and Volume Forecast, by End User

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.10.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.10.3. Market Revenue and Volume Forecast, by Age Group

13.3.10.4. Market Revenue and Volume Forecast, by End User

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.11.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.11.3. Market Revenue and Volume Forecast, by Age Group

13.3.11.4. Market Revenue and Volume Forecast, by End User

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.3. Market Revenue and Volume Forecast, by Age Group

13.4.4. Market Revenue and Volume Forecast, by End User

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.6.3. Market Revenue and Volume Forecast, by Age Group

13.4.6.4. Market Revenue and Volume Forecast, by End User

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.8.3. Market Revenue and Volume Forecast, by Age Group

13.4.8.4. Market Revenue and Volume Forecast, by End User

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.10.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.10.3. Market Revenue and Volume Forecast, by Age Group

13.4.10.4. Market Revenue and Volume Forecast, by End User

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.11.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.11.3. Market Revenue and Volume Forecast, by Age Group

13.4.11.4. Market Revenue and Volume Forecast, by End User

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Vaccine Type

13.5.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.3. Market Revenue and Volume Forecast, by Age Group

13.5.4. Market Revenue and Volume Forecast, by End User

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.5.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.6.3. Market Revenue and Volume Forecast, by Age Group

13.5.6.4. Market Revenue and Volume Forecast, by End User

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Vaccine Type

13.5.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.8.3. Market Revenue and Volume Forecast, by Age Group

13.5.8.4. Market Revenue and Volume Forecast, by End User

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. Sanofi Pasteur

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. GSK plc

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Bharat Biotech (Covaxin, Typbar)

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Sinovac Biotech Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Serum Institute of India (SII)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Pfizer Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Panacea Biotec Ltd.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. IDT Biologika

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Haffkine Bio-Pharmaceutical Corporation Ltd.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Bio Farma (Indonesia)

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The inactivated vaccines market size is expected to increase from USD 42.97 billion in 2024 to USD 75.09 billion by 2034.

The inactivated vaccines market is expected to grow at a compound annual growth rate (CAGR) of around 5.74% from 2025 to 2034.

The major players in the inactivated vaccines market include Sanofi Pasteur, GSK plc, Bharat Biotech (Covaxin, Typbar), Sinovac Biotech Ltd., Sinopharm (CNBG), Serum Institute of India (SII), Pfizer Inc., Valneva SE, Moderna, Inc.,Biological E. Limited, Panacea Biotec Ltd., Chumakov Institute of Poliomyelitis and Viral Encephalitides (Russia), IDT Biologika, Emergent BioSolutions, Novavax, Inc.,Incepta Vaccine Ltd. (Bangladesh), Haffkine Bio-Pharmaceutical Corporation Ltd., Bio Farma (Indonesia), Instituto Butantan (Brazil), and Walvax Biotechnology Co., Ltd. (China).

The driving factors of the inactivated vaccines market are the increasing number of vaccinations administered in hospitals and the expansion of home care settings are also driving market growth

Asia Pacific region will lead the global inactivated vaccines market during the forecast period 2025 to 2034.